Literature DB >> 8135344

Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate.

A Enz1, G Shapiro, A Chappuis, A Dattler.   

Abstract

Currently, protein phosphatase 2B (calcineurin) activity is assayed based on release of [32P]phosphate from a 19-amino acid peptide (partial sequence of the regulatory subunit of cAMP-dependent protein kinase) following its [32P]ATP phosphorylation using the catalytic subunit of cAMP-dependent protein kinase. This sensitive method consumes a large amount of radioactivity and is therefore problematic as a screening method for calcineurin inhibitors. We have developed an alternative nonradioactive enzyme assay in which both phosphorylation by protein kinase and dephosphorylation by calcineurin are monitored by the simultaneous quantitative determination of phosphorylated and non-phosphorylated peptide using HPLC on an RP18 column with uv detection. The method allows the measurement of enzyme kinetics as well as the characterization of potential inhibitors. The method is comparable in sensitivity to the radioactive assay. Since calcineurin is commercially available and the substrate can be prepared in a sufficient amount, this method can be used for screening purposes. An important advantage of this new method, due to the obviation of radioactivity, is the facilitation of kinetic determinations at high substrate concentrations and the increased specificity (better identification of substrate and product). The nonradioactive substrate is very stable and can be stored for months in comparison with the 32P-peptide, which has to be freshly prepared every few weeks due to the decay of the nuclid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135344     DOI: 10.1006/abio.1994.1018

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  13 in total

1.  Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients.

Authors:  M Büchler; P Leibenguth; C Le Guellec; A Carayon; H Watier; F Odoul; E Autret-Leca; Y Lebranchu; G Paintaud
Journal:  Eur J Clin Pharmacol       Date:  2004-11-20       Impact factor: 2.953

2.  3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

3.  Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.

Authors:  Miranda Brun; Darryl D Glubrecht; Shairaz Baksh; Roseline Godbout
Journal:  J Biol Chem       Date:  2013-07-09       Impact factor: 5.157

4.  Different effects of CsA and FK506 on aquaporin-2 abundance in rat primary cultured collecting duct cells.

Authors:  Markus M Rinschen; Jens Klokkers; Hermann Pavenstädt; Ute Neugebauer; Eberhard Schlatter; Bayram Edemir
Journal:  Pflugers Arch       Date:  2011-07-20       Impact factor: 3.657

5.  Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid-β revealed by a novel fluorescence resonance energy transfer assay.

Authors:  Hai-Yan Wu; Eloise Hudry; Tadafumi Hashimoto; Kengo Uemura; Zhan-Yun Fan; Oksana Berezovska; Cynthia L Grosskreutz; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

6.  The protein phosphatases of Synechocystis sp. strain PCC 6803: open reading frames sll1033 and sll1387 encode enzymes that exhibit both protein-serine and protein-tyrosine phosphatase activity in vitro.

Authors:  Renhui Li; M Ben Potters; Liang Shi; Peter J Kennelly
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

7.  Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour.

Authors:  Sachiko Taniguchi; Takanobu Nakazawa; Asami Tanimura; Yuji Kiyama; Tohru Tezuka; Ayako M Watabe; Norikazu Katayama; Kazumasa Yokoyama; Takeshi Inoue; Hiroko Izumi-Nakaseko; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura; Hisashi Umemori; Takafumi Inoue; Niall P Murphy; Kouichi Hashimoto; Masanobu Kano; Toshiya Manabe; Tadashi Yamamoto
Journal:  EMBO J       Date:  2009-10-15       Impact factor: 11.598

8.  Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression.

Authors:  Małgorzata Rydzanicz; Małgorzata Wachowska; Erik C Cook; Paweł Lisowski; Bożena Kuźniewska; Krystyna Szymańska; Sebastian Diecke; Alessandro Prigione; Krzysztof Szczałuba; Aleksandra Szybińska; Agnieszka Koppolu; Victor Murcia Pienkowski; Joanna Kosińska; Małgorzata Wiweger; Grażyna Kostrzewa; Małgorzata Brzozowska; Dorota Domańska-Pakieła; Elżbieta Jurkiewicz; Piotr Stawiński; Agnieszka Gromadka; Piotr Zielenkiewicz; Urszula Demkow; Magdalena Dziembowska; Jacek Kuźnicki; Trevor P Creamer; Rafał Płoski
Journal:  Eur J Hum Genet       Date:  2018-09-25       Impact factor: 4.246

9.  Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors.

Authors:  Abhisek Mukherjee; Kathleen Syeb; John Concannon; Keri Callegari; Claudio Soto; Marcie A Glicksman
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

10.  Mitochondria to nucleus stress signaling: a distinctive mechanism of NFkappaB/Rel activation through calcineurin-mediated inactivation of IkappaBbeta.

Authors:  Gopa Biswas; Hindupur K Anandatheerthavarada; Mone Zaidi; Narayan G Avadhani
Journal:  J Cell Biol       Date:  2003-05-05       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.